Gneiss C - Search Results

1

Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments.

Khalil M, Reindl M, Lutterotti A, Kuenz B, Ehling R, Gneiss C, Lackner P, Deisenhammer F, Berger T. Khalil M, et al. Among authors: gneiss c. J Neuroimmunol. 2006 May;174(1-2):147-56. doi: 10.1016/j.jneuroim.2006.01.012. Epub 2006 Mar 6. J Neuroimmunol. 2006. PMID: 16516980 Clinical Trial.

2

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil M, Berger T, Deisenhammer F. Gneiss C, et al. Mult Scler. 2004 Oct;10(5):507-10. doi: 10.1191/1352458504ms1074oa. Mult Scler. 2004. PMID: 15471365

3

Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.

Gneiss C, Tripp P, Ehling R, Khalil M, Lutterotti A, Egg R, Mayringer I, Künz B, Berger T, Reindl M, Deisenhammer F. Gneiss C, et al. J Neuroimmunol. 2006 May;174(1-2):174-9. doi: 10.1016/j.jneuroim.2006.01.017. Epub 2006 Mar 23. J Neuroimmunol. 2006. PMID: 16556466 Clinical Trial.

4

Epitope specificity of neutralizing antibodies against IFN-beta.

Gneiss C, Reindl M, Berger T, Lutterotti A, Ehling R, Egg R, Deisenhammer F. Gneiss C, et al. J Interferon Cytokine Res. 2004 May;24(5):283-90. doi: 10.1089/107999004323065066. J Interferon Cytokine Res. 2004. PMID: 15153311

5

Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis.

Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer F, Reindl M, Berger T. Kuenz B, et al. Among authors: gneiss c. J Neuroimmunol. 2005 Oct;167(1-2):143-9. doi: 10.1016/j.jneuroim.2005.06.019. J Neuroimmunol. 2005. PMID: 16040131

6

Increased serum levels of soluble CD14 indicate stable multiple sclerosis.

Lutterotti A, Kuenz B, Gredler V, Khalil M, Ehling R, Gneiss C, Egg R, Deisenhammer F, Berger T, Reindl M. Lutterotti A, et al. Among authors: gneiss c. J Neuroimmunol. 2006 Dec;181(1-2):145-9. doi: 10.1016/j.jneuroim.2006.09.002. Epub 2006 Oct 13. J Neuroimmunol. 2006. PMID: 17046070

7

Natalizumab treatment reduces endothelial activity in MS patients.

Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F. Millonig A, et al. Among authors: gneiss c. J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23. J Neuroimmunol. 2010. PMID: 20739072

8

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F. Hegen H, et al. Among authors: gneiss c. Mult Scler. 2012 May;18(5):610-5. doi: 10.1177/1352458511426738. Epub 2011 Oct 19. Mult Scler. 2012. PMID: 22013146

9

Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.

Ehling R, Lutterotti A, Wanschitz J, Khalil M, Gneiss C, Deisenhammer F, Reindl M, Berger T. Ehling R, et al. Among authors: gneiss c. Mult Scler. 2004 Dec;10(6):601-6. doi: 10.1191/1352458504ms1100oa. Mult Scler. 2004. PMID: 15584481

10

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.

Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F. Gneiss C, et al. Mult Scler. 2006 Dec;12(6):731-7. doi: 10.1177/1352458506070941. Mult Scler. 2006. PMID: 17263000

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page